Table 4.
Factors associated with reaching the endpoint in the IgAN-NS and IgAN-NR without CR.
| Factors | HR | CI | p | HR | CI | p |
|---|---|---|---|---|---|---|
| Age | 1 | 0.98–1.02 | 1 | |||
| Serum albumin | 0.22 | 0.11–0.47 | <.001 | 0.21 | 0.1–0.45 | <.001 |
| Body mass index | 1.01 | 0.98–1.05 | .4 | |||
| C1 | 1.05 | 0.57–1.92 | .9 | |||
| E1 | 1.42 | 0.62–3.24 | .4 | |||
| Fibrinogen | 1.96 | 0.82–4.7 | .1 | |||
| Hemoglobin | 0.97 | 0.92–1.02 | .2 | |||
| HDL-cholesterol | 0.59 | 0.22–1.59 | .3 | |||
| LDL-cholesterol | 1.12 | 0.89–1.42 | .3 | |||
| Mean arterial pressure | 1.01 | 0.99–1.03 | .5 | |||
| M1 | 1.28 | 1.01–1.61 | .04 | 1.3 | 1.02–1.66 | .04 |
| Proteinuria | 1.01 | 0.91–1.12 | .8 | |||
| Serum creatinine | 1.06 | 0.96–1.17 | .3 | |||
| Male | 1.03 | 0.57–1.89 | .9 | |||
| S1 | 1.96 | 0.58–6.67 | .3 | |||
| Total cholesterol | 1.02 | 0.87–1.19 | .8 | |||
| Triglyceride | 1.08 | 0.92–1.26 | .3 | |||
| T1 | 1.53 | 0.54–4.39 | .4 | |||
| T2 | 0.67 | 0.3–1.49 | .3 | |||
| Serum IgA | 1.01 | 0.99–1.03 | .5 | |||
| Uric acid | 1.15 | 1–1.33 | .05 | 1.14 | 0.98–1.33 | .08 |
| Urine red blood cell count | 1.01 | 0.98–1.04 | .6 | |||
| Renin-angiotensinsystem inhibitor | 0.97 | 0.88–1.06 | .5 | |||
| Steroid | 0.77 | 0.43–1.37 | .4 | |||
| Immunosuppressant | 0.69 | 0.37–1.28 | .2 |
The endpoint was referred to a continuous decline in eGFR of ≥30% from the baseline or reaching ESRD. Factors that showed statistical significance (p < .1) in univariate-Cox-regression analysis were chosen to establish a multivariate-Cox-regression model. Subsequently, the AIC using FB stepwise selection was employed to identify the best model with a minimum AIC value.
E1: endocapillary hypercellularity; M1: mesangial hypercellularity; T1-2: severity of interstitial fibrosis/tubular atrophy; S1: segmental glomerulosclerosis/adhesion; C1: presence of crescent; HR: hazard ratio; CI: confidence interval; AIC: Akaike information criterion.